On March 15th, 2022, at 11:30
To participate, please contact email@example.com
One of the most important current applications of personalized medicine is the study of the correlations between genetic variations and the emergence of tumor phenotypes in specific human groups in order to provide more personalized treatments. In particular, pharmacogenomics aims at studying the relationship between drug response and individual genomic variations. In cancer treatment, however, the overall effectiveness of this gene-based approach is impaired by the genetic and phenotypic heterogeneity of tumor cells, thus making the pharmacogenomics in cancer treatment problematic. The purpose of this talk is threefold: first, to analyze the levels of organization of tumor heterogeneity; secondly, to explore the complexity of tumor heterogeneity; finally, to estimate the epistemological and practical consequences of such a complexity for the pharmacogenomics in the personalized cancer treatment.
Bio: Guglielmo Militello (EHU/UPV)